Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;14(5):965-976.
doi: 10.3233/JPD-240075.

Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain

Melissa Scholefield  1 , Stephanie J Church  1 , Jingshu Xu  2 , Stefano Patassini  2 , Garth J S Cooper  1   2
Affiliations

Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain

Melissa Scholefield et al. J Parkinsons Dis. 2024.

Abstract

Background: Localized pantothenic acid deficiencies have been observed in several neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and Huntington's disease (HD), indicating downstream energetic pathway perturbations. However, no studies have yet been performed to see whether such deficiencies occur across the dementia with Lewy bodies (DLB) brain, or what the pattern of such dysregulation may be.

Objective: Firstly, this study aimed to quantify pantothenic acid levels across ten regions of the brain in order to determine the localization of any pantothenic acid dysregulation in DLB. Secondly, the localization of pantothenic acid alterations was compared to that previously in AD, PDD, and HD brains.

Methods: Pantothenic acid levels were determined in 20 individuals with DLB and 19 controls by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) across ten brain regions. Case-control differences were determined by nonparametric Mann-Whitney U test, with the calculation of S-values, risk ratios, E-values, and effect sizes. The results were compared with those previously obtained in DLB, AD, and HD.

Results: Pantothenic acid levels were significantly decreased in six of the ten investigated brain regions: the pons, substantia nigra, motor cortex, middle temporal gyrus, primary visual cortex, and hippocampus. This level of pantothenic acid dysregulation is most similar to that of the AD brain, in which pantothenic acid is also decreased in the motor cortex, middle temporal gyrus, primary visual cortex, and hippocampus. DLB appears to differ from other neurodegenerative diseases in being the only of the four to not show pantothenic acid dysregulation in the cerebellum.

Conclusions: Pantothenic acid deficiency appears to be a shared mechanism of several neurodegenerative diseases, although differences in the localization of this dysregulation may contribute to the differing clinical pathways observed in these conditions.

Keywords: Lewy body dementia; Pantothenic acid; UHPLC–MS/MS; dementia with Lewy bodies; mass spectrometry; metabolomics; vitamin B5.

Plain language summary

Decreases in a molecule called pantothenic acid (also known as vitamin B5) have been observed in several areas of the brain in multiple dementia disease, including Alzheimer’s disease, Parkinson’s disease dementia, and Huntington’s disease. However, it is unknown whether such changes also occur in another dementia disease, dementia with Lewy bodies, which shows many of the same symptoms and molecular changes as these conditions. As such, this study was performed in order to determine if and where changes in pantothenic acid occur throughout the dementia with Lewy bodies brain. Using a methodology called liquid chromatography–mass spectrometry, which is able to measure pantothenic acid levels in a highly precise manner in brain tissues, we found that several regions of the dementia with Lewy bodies brain show decreases in pantothenic acid, including some involved in movement such as the substantia nigra and motor cortex, as well as regions associated with cognition and memory such as the hippocampus—looking most similar to the pattern of changes already seen in Alzheimer’s disease. It is possible that these changes contribute to the progression of dementia with Lewy bodies; however, further studies need to be performed to determine at what point these changes happen during the disease and how they may contribute to the development of symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

Figures

Fig. 1
Fig. 1
Pantothenic acid concentrations in DLB cases and controls. Figure shows mean urea concentrations±95% confidence intervals in μM/Kg. Case–control differences were determined using Mann–Whitney U test. CB, Cerebellum; SN, Substantia nigra; MCX, Motor cortex; CG, Cingulate gyrus; MED, Medulla; MTG, Middle temporal gyrus; PVC, Primary visual cortex; PUT, Putamen; HP, Hippocampus.
Fig. 2
Fig. 2
Comparison of pantothenic acid alterations in DLB, PDD, AD, and HD brains. Blue regions indicate decreases in pantothenic acid. Grey regions indicate no changes in pantothenic acid. Grey dotted shading indicates that region was not investigated in that condition. CB, Cerebellum; CG, Cingulate Gyrus; ENT, Entorhinal Cortex; HP, Hippocampus; MED, Medulla; MCX, Motor Cortex; MFG, Middle frontal gyrus; MTG, Middle Temporal Gyrus; PUT, Putamen; PVC, Primary visual cortex; SN, Substantia Nigra.
See this image and copyright information in PMC

References

    1. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O’Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K (2017) Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88–100. - PMC - PubMed
    1. Cabrero FR, Morrison EH (2022) Lewy bodies. In StatPearls [Internet], StatPearls Publishing. - PubMed
    1. Chin KS, Yassi N, Churilov L, Masters CL, Watson R (2020) Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis. Parkinsonism Relat Disord 80, 184–193. - PubMed
    1. Twohig D, Nielsen HM (2019) alpha-synuclein in the pathophysiology of Alzheimer’s disease. Mol Neurodegener 14, 23. - PMC - PubMed
    1. Zekry D, Hauw JJ, Gold G (2002) Mixed dementia: Epidemiology, diagnosis, and treatment. J Am Geriatr Soc 50, 1431–1438. - PubMed

Publication types

Substances